S&P 500   3,923.03 (-4.06%)
DOW   31,458.89 (-3.66%)
QQQ   290.66 (-5.07%)
AAPL   140.48 (-5.87%)
MSFT   254.00 (-4.80%)
FB   192.68 (-4.91%)
GOOGL   2,247.00 (-3.54%)
AMZN   2,132.67 (-7.57%)
TSLA   704.55 (-7.49%)
NVDA   169.67 (-6.66%)
BABA   87.45 (-4.94%)
NIO   15.77 (-5.17%)
AMD   96.06 (-6.26%)
CGC   5.57 (-5.43%)
MU   70.80 (-4.94%)
T   20.19 (-1.85%)
GE   74.98 (-1.86%)
F   12.74 (-5.84%)
DIS   104.23 (-4.06%)
AMC   12.63 (-2.09%)
PFE   50.18 (-2.26%)
PYPL   77.01 (-3.44%)
NFLX   176.51 (-7.37%)
S&P 500   3,923.03 (-4.06%)
DOW   31,458.89 (-3.66%)
QQQ   290.66 (-5.07%)
AAPL   140.48 (-5.87%)
MSFT   254.00 (-4.80%)
FB   192.68 (-4.91%)
GOOGL   2,247.00 (-3.54%)
AMZN   2,132.67 (-7.57%)
TSLA   704.55 (-7.49%)
NVDA   169.67 (-6.66%)
BABA   87.45 (-4.94%)
NIO   15.77 (-5.17%)
AMD   96.06 (-6.26%)
CGC   5.57 (-5.43%)
MU   70.80 (-4.94%)
T   20.19 (-1.85%)
GE   74.98 (-1.86%)
F   12.74 (-5.84%)
DIS   104.23 (-4.06%)
AMC   12.63 (-2.09%)
PFE   50.18 (-2.26%)
PYPL   77.01 (-3.44%)
NFLX   176.51 (-7.37%)
S&P 500   3,923.03 (-4.06%)
DOW   31,458.89 (-3.66%)
QQQ   290.66 (-5.07%)
AAPL   140.48 (-5.87%)
MSFT   254.00 (-4.80%)
FB   192.68 (-4.91%)
GOOGL   2,247.00 (-3.54%)
AMZN   2,132.67 (-7.57%)
TSLA   704.55 (-7.49%)
NVDA   169.67 (-6.66%)
BABA   87.45 (-4.94%)
NIO   15.77 (-5.17%)
AMD   96.06 (-6.26%)
CGC   5.57 (-5.43%)
MU   70.80 (-4.94%)
T   20.19 (-1.85%)
GE   74.98 (-1.86%)
F   12.74 (-5.84%)
DIS   104.23 (-4.06%)
AMC   12.63 (-2.09%)
PFE   50.18 (-2.26%)
PYPL   77.01 (-3.44%)
NFLX   176.51 (-7.37%)
S&P 500   3,923.03 (-4.06%)
DOW   31,458.89 (-3.66%)
QQQ   290.66 (-5.07%)
AAPL   140.48 (-5.87%)
MSFT   254.00 (-4.80%)
FB   192.68 (-4.91%)
GOOGL   2,247.00 (-3.54%)
AMZN   2,132.67 (-7.57%)
TSLA   704.55 (-7.49%)
NVDA   169.67 (-6.66%)
BABA   87.45 (-4.94%)
NIO   15.77 (-5.17%)
AMD   96.06 (-6.26%)
CGC   5.57 (-5.43%)
MU   70.80 (-4.94%)
T   20.19 (-1.85%)
GE   74.98 (-1.86%)
F   12.74 (-5.84%)
DIS   104.23 (-4.06%)
AMC   12.63 (-2.09%)
PFE   50.18 (-2.26%)
PYPL   77.01 (-3.44%)
NFLX   176.51 (-7.37%)
NASDAQ:ARDS

Aridis Pharmaceuticals (ARDS) Stock Forecast, Price & News

$1.06
-0.19 (-15.20%)
(As of 05/18/2022 03:30 PM ET)
Add
Compare
Today's Range
$1.06
$1.16
50-Day Range
$0.91
$1.80
52-Week Range
$0.88
$7.72
Volume
937 shs
Average Volume
57,362 shs
Market Capitalization
$18.76 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.42
30 days | 90 days | 365 days | Advanced Chart
Receive ARDS News and Ratings via Email

Sign-up to receive the latest news and ratings for Aridis Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Aridis Pharmaceuticals logo

About Aridis Pharmaceuticals

Aridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, focuses on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that is in Phase III pivotal trials for the treatment of lung infections resulting from S. aureus alphatoxin. The company is also developing AR-320 is a fully human IgG1 monoclonal antibody targeting S. aureus alpha toxin to treat infections caused by methicillin-resistant Staphylococcus aureus and methicillin-susceptible S. aureus; AR-105, a fully human IgG1 mAb, which is in Phase II trials to target gram-negative bacteria P. aeruginosa; AR-101, a human IgM mAb, which is in Phase IIa clinical trials for the treatment of hospital-acquired pneumonia (HAP)and ventilator-associated pneumonia (VAP) caused by P. aeruginosa serotype O11; AR-401 that is in preclinical stage to treat infections caused by Acinetobacter baumannii; AR-201, a fully human IgG1 mAb preclinical program for respiratory syncytial virus; and AR-501, an anti-infective therapy, which is in Phase I/IIa clinical trial to manage chronic lung infections in cystic fibrosis patients. In addition, it is developing AR-712 and AR-701, a cocktail of two fully human immunoglobulin 1, or IgG1, mAbs, which is in Phase I/II clinical for the treatment of mild to moderate non-hospitalized COVID-19 patients. Aridis Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Los Gatos, California.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ARDS
Employees
33
Year Founded
N/A

Sales & Book Value

Annual Sales
$1.53 million
Book Value
($0.93) per share

Profitability

Net Income
$-42.19 million
Pretax Margin
-2,748.73%

Debt

Price-To-Earnings

Miscellaneous

Free Float
14,498,000
Market Cap
$18.76 million
Optionable
Not Optionable

Company Calendar

Last Earnings
5/16/2022
Today
5/18/2022
Next Earnings (Estimated)
8/11/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

1.82 out of 5 stars

Medical Sector

789th out of 1,426 stocks

Pharmaceutical Preparations Industry

380th out of 680 stocks

Analyst Opinion: 3.5Community Rank: 4.1Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.6 5 -4 -3 -2 -1 -













Aridis Pharmaceuticals (NASDAQ:ARDS) Frequently Asked Questions

Is Aridis Pharmaceuticals a buy right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aridis Pharmaceuticals in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Aridis Pharmaceuticals stock.
View analyst ratings for Aridis Pharmaceuticals
or view top-rated stocks.

Are investors shorting Aridis Pharmaceuticals?

Aridis Pharmaceuticals saw a increase in short interest in April. As of April 30th, there was short interest totaling 109,500 shares, an increase of 52.1% from the April 15th total of 72,000 shares. Based on an average daily volume of 324,500 shares, the days-to-cover ratio is presently 0.3 days.
View Aridis Pharmaceuticals' Short Interest
.

When is Aridis Pharmaceuticals' next earnings date?

Aridis Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, August 11th 2022.
View our earnings forecast for Aridis Pharmaceuticals
.

How were Aridis Pharmaceuticals' earnings last quarter?

Aridis Pharmaceuticals, Inc. (NASDAQ:ARDS) posted its quarterly earnings results on Monday, May, 16th. The company reported ($0.44) earnings per share for the quarter, beating analysts' consensus estimates of ($0.51) by $0.07.
View Aridis Pharmaceuticals' earnings history
.

What price target have analysts set for ARDS?

2 brokerages have issued 1-year price targets for Aridis Pharmaceuticals' shares. Their forecasts range from $10.00 to $19.00. On average, they expect Aridis Pharmaceuticals' share price to reach $14.50 in the next year. This suggests a possible upside of 1,242.6% from the stock's current price.
View analysts' price targets for Aridis Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Aridis Pharmaceuticals' key executives?
Aridis Pharmaceuticals' management team includes the following people:
  • Dr. Vu L. Truong Ph.D., Founder, CEO, Chief Scientific Officer & Director (Age 58, Pay $566.12k)
  • Dr. Hasan Jafri M.D., Chief Medical Officer
  • Mr. Fred Kurland J.D., M.B.A., Chief Financial Officer (Age 71)
  • Mr. Jeffrey J. Fessler Esq., J.D., Acting Gen. Counsel (Age 59)
What other stocks do shareholders of Aridis Pharmaceuticals own?
When did Aridis Pharmaceuticals IPO?

(ARDS) raised $28 million in an IPO on Tuesday, August 14th 2018. The company issued 2,000,000 shares at a price of $13.00-$15.00 per share. Cantor acted as the underwriter for the IPO and Maxim Group and Northland Capital Markets were co-managers.

What is Aridis Pharmaceuticals' stock symbol?

Aridis Pharmaceuticals trades on the NASDAQ under the ticker symbol "ARDS."

Who are Aridis Pharmaceuticals' major shareholders?

Aridis Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional investors include Commonwealth Equity Services LLC (3.26%), Vanguard Group Inc. (2.96%), Minot Wealth Management LLC (0.36%), Group One Trading L.P. (0.15%) and Concourse Financial Group Securities Inc. (0.00%). Company insiders that own Aridis Pharmaceuticals stock include John F Hamilton and Vu Truong.
View institutional ownership trends for Aridis Pharmaceuticals
.

Which institutional investors are buying Aridis Pharmaceuticals stock?

ARDS stock was bought by a variety of institutional investors in the last quarter, including Commonwealth Equity Services LLC, Minot Wealth Management LLC, Group One Trading L.P., and Vanguard Group Inc.. Company insiders that have bought Aridis Pharmaceuticals stock in the last two years include John F Hamilton, and Vu Truong.
View insider buying and selling activity for Aridis Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Aridis Pharmaceuticals?

Shares of ARDS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Aridis Pharmaceuticals' stock price today?

One share of ARDS stock can currently be purchased for approximately $1.08.

How much money does Aridis Pharmaceuticals make?

Aridis Pharmaceuticals has a market capitalization of $19.12 million and generates $1.53 million in revenue each year. The company earns $-42.19 million in net income (profit) each year or ($3.790010) on an earnings per share basis.

How many employees does Aridis Pharmaceuticals have?

Aridis Pharmaceuticals employs 33 workers across the globe.

What is Aridis Pharmaceuticals' official website?

The official website for Aridis Pharmaceuticals is www.aridispharma.com.

How can I contact Aridis Pharmaceuticals?

Aridis Pharmaceuticals' mailing address is 5941 Optical Ct, San Jose CA, 95138. The company can be reached via phone at (408) 385-1742, via email at [email protected], or via fax at 408-960-3822.

This page was last updated on 5/18/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.